Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech, Persistent Developing Software for CE Sequencing Data Analysis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Persistent Systems today announced that it has partnered with Life Technologies to develop a new software platform for the analysis of sequencing data generated by capillary electrophoresis instruments.

Persistent and the Fragment and Sequence Genomics division of Life Tech will build the sequencing and fragment analysis software for CE sequencing platforms that will be submitted for approval by the US Food and Drug Administration, Persistent said. The software solutions company, which has offices in India and San Jose, Calif., also will provide services to integrate assays from third-party vendors.

The new platform "represents an advanced genomic technology for clinics taking a step towards making personalized medicine a reality to combat critical human diseases like cancer," Persistent said in a statement.

Financial and other terms of the deal were not disclosed.

"Our partnership with Persistent Systems allow us to take the next step in developing molecular diagnostic solutions that leverage our gold standard sequencing and fragment analysis technology," said Todd Laird, VP and general manager of Life Tech's Fragment and Sequence Genomics division.

Life Tech officials confirmed the alliance but declined to provide additional details.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.